CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2024
0mins
Source: accesswire
Event Announcement: CNS Pharmaceuticals will host a Virtual Analyst & Investor Day on December 11, 2024, featuring discussions on glioblastoma multiforme (GBM) and the company's drug candidates, Berubicin and TPI 287, with insights from key opinion leaders in neuro-oncology.
Company Overview: CNS Pharmaceuticals is focused on developing innovative treatments for aggressive brain cancers, particularly GBM, with Berubicin being the first anthracycline that can cross the blood-brain barrier.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
